{
  "docId": "019de510-c0ed-7699-8bf7-892eb75d2a26",
  "docSlug": "43fded91ff08c45a8a96283b7b8b25cc",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 14 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 14,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "The slide uses a list-based layout to summarize key company pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de510-c0ed-7699-8bf7-892eb75d2a26/3",
  "deckHref": "/decks/019de510-c0ed-7699-8bf7-892eb75d2a26",
  "deckJsonHref": "/decks/019de510-c0ed-7699-8bf7-892eb75d2a26.json",
  "deckAnchorHref": "/decks/019de510-c0ed-7699-8bf7-892eb75d2a26#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.22,
        "w": 0.88,
        "x": 0.1,
        "y": 0.86
      },
      "kind": "list",
      "text": "Corporate Update. Raised approx. $80M in two transactions principally with top tier US specialist Life Science investors. MaxCyte will focus future investment into high value expansion opportunities to support partner’s clinical advancement and commercial launches of therapies enabled by MaxCyte.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "138a8a6e-a751-4934-9958-93103735f1d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.88,
        "x": 0.1,
        "y": 0.38
      },
      "kind": "list",
      "text": "“Go to” non-viral delivery technology critical for manufacturing of next-generation cell therapies. Total of 12 announced clinical and commercial partnerships; added four additional strategic license customers in the last 12 months; strategic licenses now granted for 140+ cell therapy programs, 100+ for clinical use excluding CARMA™. Total potential pre-commercial milestone payments now exceed $950m.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7de7a32a-1280-48cc-9d9a-63376daf3940",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.88,
        "x": 0.1,
        "y": 0.14
      },
      "kind": "list",
      "text": "Market-leading manufacturer of cell engineering enabling technologies based on proprietary flow electroporation (the ExPERT™ platform). High efficiency, reproducible, scalable non-viral cell engineering system; proprietary platform unlocks potential of engineered stem cells and immune cells (NK, T cells, etc.). Revenue model is highly recurring, enables MaxCyte to realize razor/razor blade economics and capture a part of product economics, and delivers high margin (~90% gm across the portfolio).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de2db6e9-d894-463c-a69f-3c8338688357",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.88,
        "x": 0.1,
        "y": 0.62
      },
      "kind": "list",
      "text": "Robust full-year 2020 results; expect 2021 revenue growth to accelerate. FY20 revenues of $26.2m, strong year-over-year growth of 21%. Expect strong underlying revenue growth in our cell therapy business driven by clinical progression of our existing customers and new customer acquisition; strategic partnership pipeline coming into 2021 is the largest it has been.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efc08ed1-cd18-4afb-8e31-4c99db6e4489",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.85,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Global partner of choice for non-viral cell engineering technology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98a24dad-ae44-432d-8805-ef87ce3bbdf6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "81ccd13a-aa54-409b-94aa-7b4f456552ea",
      "evidence": "type: executive_summary",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 3,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "e1ff3769-61bf-4884-a5aa-e2b29e2c49b2",
      "evidence": "The executive summary presents MaxCyte as a global partner of choice",
      "position": 0,
      "objective": "Why MaxCyte?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}